GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CSL Ltd (OTCPK:CMXHF) » Definitions » ROE % Adjusted to Book Value

CSL (CMXHF) ROE % Adjusted to Book Value : 4.21% (As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is CSL ROE % Adjusted to Book Value?

CSL's ROE % for the quarter that ended in Dec. 2023 was 23.07%. CSL's PB Ratio for the quarter that ended in Dec. 2023 was 5.48. CSL's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was 4.21%.


CSL ROE % Adjusted to Book Value Historical Data

The historical data trend for CSL's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSL ROE % Adjusted to Book Value Chart

CSL Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.17 2.60 2.69 3.23 2.53

CSL Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.31 1.14 3.58 1.27 4.21

Competitive Comparison of CSL's ROE % Adjusted to Book Value

For the Biotechnology subindustry, CSL's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CSL's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CSL's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where CSL's ROE % Adjusted to Book Value falls into.



CSL ROE % Adjusted to Book Value Calculation

CSL's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=14.45% / 5.72
=2.53%

CSL's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=23.07% / 5.48
=4.21%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CSL ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of CSL's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


CSL (CMXHF) Business Description

Industry
Traded in Other Exchanges
Address
655 Elizabeth Street, Melbourne, VIC, AUS, 3000
CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include non-plasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.